Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 375 of 885 entries
View as:

Nipocalimab in Moderate to Severe Sjogren's Disease

Phase: N/A Priority: Normal
NCT ID: NCT06741969 Org: User:
Start: 12/04/24 End: 06/29/30 Due: 06/29/31

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04644770 Org: User:
Start: 11/12/20 End: 05/26/28 Due: 05/26/29

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Phase: N/A Priority: Normal
NCT ID: NCT06877676 Org: User:
Start: - End: - Due: -

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

Phase: N/A Priority: Normal
NCT ID: NCT06500884 Org: User:
Start: 08/26/24 End: 10/18/27 Due: 10/18/28

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06919965 Org: User:
Start: 09/30/25 End: 03/16/32 Due: 03/16/33

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06934226 Org: User:
Start: 04/15/25 End: 12/29/27 Due: 12/29/28

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Phase: N/A Priority: Normal
NCT ID: NCT04658862 Org: User:
Start: 12/07/20 End: 12/31/28 Due: 12/31/29

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT06651229 Org: User:
Start: 03/21/25 End: 12/01/28 Due: 12/01/29

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06662786 Org: User:
Start: 10/18/24 End: 12/15/32 Due: 12/15/33

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Phase: N/A Priority: Normal
NCT ID: NCT01809327 Org: User:
Start: 06/04/13 End: 12/02/14 Due: 12/02/15

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

Phase: N/A Priority: Normal
NCT ID: NCT02924766 Org: User:
Start: 10/03/16 End: 07/19/19 Due: 07/19/20

A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04474210 Org: User:
Start: 08/19/20 End: 11/30/20 Due: 11/30/21

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Phase: N/A Priority: Normal
NCT ID: NCT02065752 Org: User:
Start: 02/28/14 End: 04/30/14 Due: 04/30/15

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

Phase: N/A Priority: Normal
NCT ID: NCT02993237 Org: User:
Start: 01/23/17 End: 05/25/17 Due: 05/25/18

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Phase: N/A Priority: Normal
NCT ID: NCT01230827 Org: User:
Start: 12/31/10 End: 05/31/14 Due: 05/31/15

A Study of JNJ-73763989 in Adult Participants With Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT04963738 Org: User:
Start: 09/22/21 End: 10/17/22 Due: 10/17/23

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

Phase: N/A Priority: Normal
NCT ID: NCT02243189 Org: User:
Start: 10/31/14 End: 12/31/14 Due: 12/31/15

A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses

Phase: N/A Priority: Normal
NCT ID: NCT04544826 Org: User:
Start: 10/16/20 End: 08/05/21 Due: 08/05/22

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Phase: N/A Priority: Normal
NCT ID: NCT03249506 Org: User:
Start: 05/12/16 End: 11/01/17 Due: 11/01/18

A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT05071664 Org: User:
Start: 10/25/21 End: 08/06/24 Due: 08/06/25

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03180762 Org: User:
Start: 05/30/17 End: 09/25/17 Due: 09/25/18

A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01978548 Org: User:
Start: 12/31/13 End: 04/30/15 Due: 04/30/16

A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03066687 Org: User:
Start: 03/14/17 End: 05/12/17 Due: 05/12/18

A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03723746 Org: User:
Start: 10/25/18 End: 12/16/19 Due: 12/16/20

A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01508182 Org: User:
Start: 01/31/12 End: 03/31/12 Due: 03/31/13